Literature DB >> 22183222

ST analysis of the fetal electrocardiogram in intrapartum fetal monitoring: a meta-analysis.

Jeroen H Becker1, Leon Bax, Isis Amer-Wåhlin, Kati Ojala, Christophe Vayssière, Michelle E M H Westerhuis, Ben-Willem Mol, Gerard H A Visser, Karel Maršál, Anneke Kwee, Karel G M Moons.   

Abstract

OBJECTIVE: To compare the effects of ST-waveform analysis in combination with cardiotocography with conventional cardiotocography for intrapartum fetal monitoring. DATA SOURCES: We searched MEDLINE, Embase, and PubMed for randomized controlled trials (RCTs) evaluating ST-waveform analysis for intrapartum fetal monitoring. METHODS OF STUDY SELECTION: We identified RCTs that compared ST-waveform analysis and conventional cardiotocography for intrapartum fetal monitoring of singleton pregnancies in cephalic presentation beyond 34 weeks of gestation and evaluating at least one of the following: metabolic acidosis, umbilical cord pH less than 7.15, umbilical cord pH less than 7.10, umbilical cord pH less than 7.05, umbilical cord pH less than 7.00, Apgar scores less than 7 at 5 minutes, admittance to the neonatal intensive care unit, need for intubation, presence of hypoxic ischemic encephalopathy, perinatal death, operative delivery, and number of fetal blood samplings. TABULATION, INTEGRATION, AND
RESULTS: Five RCTs, which included 15,352 patients, met the selection criteria. Random-effects models were used to estimate the combined relative risks (RRs) of ST analysis compared with conventional cardiotocography. Compared with conventional cardiotocography, ST analysis showed a nonsignificant reduction in metabolic acidosis (RR 0.72, 95% confidence interval 0.43-1.19, number needed to treat [NNT] 357). ST analysis significantly reduced the incidence of additional fetal blood sampling (RR 0.59, 95% confidence interval 0.44-0.79, NNT 11), operative vaginal deliveries (RR 0.88, 95% confidence interval 0.80-0.97, NNT 64), and total operative deliveries (RR 0.94, 95% confidence interval 0.89-0.99, NNT 64). For other outcomes, no differences in effect were seen between ST analysis and conventional cardiotocography, or data were not suitable for meta-analysis.
CONCLUSION: The additional use of ST analysis for intrapartum monitoring reduced the incidence of operative vaginal deliveries and the need for fetal blood sampling but did not reduce the incidence of metabolic acidosis at birth.

Entities:  

Mesh:

Year:  2012        PMID: 22183222     DOI: 10.1097/AOG.0b013e31823d8230

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Cardiotocography combined with ST analysis versus cardiotocography combined with fetal blood sampling in deliveries with abnormal CTG: a randomized trial.

Authors:  Simon Foged Victor; Diana Bøttcher Brøndum Bach; Anna Carolina Hvelplund; Carsten Nickelsen; Jens Lyndrup; Charlotte Wilken-Jensen; Lise Jul Scharff; Tom Weber; Niels Jørgen Secher; Lone Krebs
Journal:  Arch Gynecol Obstet       Date:  2022-06-14       Impact factor: 2.344

Review 2.  A critical appraisal of the evidence for using cardiotocography plus ECG ST interval analysis for fetal surveillance in labor. Part I: the randomized controlled trials.

Authors:  Per Olofsson; Diogo Ayres-de-Campos; Jörg Kessler; Britta Tendal; Branka M Yli; Lawrence Devoe
Journal:  Acta Obstet Gynecol Scand       Date:  2014-06       Impact factor: 3.636

Review 3.  A critical appraisal of the evidence for using cardiotocography plus ECG ST interval analysis for fetal surveillance in labor. Part II: the meta-analyses.

Authors:  Per Olofsson; Diogo Ayres-de-Campos; Jörg Kessler; Britta Tendal; Branka M Yli; Lawrence Devoe
Journal:  Acta Obstet Gynecol Scand       Date:  2014-06       Impact factor: 3.636

4.  Noninvasive Fetal Electrocardiography Part II: Segmented-Beat Modulation Method for Signal Denoising.

Authors:  Angela Agostinelli; Agnese Sbrollini; Luca Burattini; Sandro Fioretti; Francesco Di Nardo; Laura Burattini
Journal:  Open Biomed Eng J       Date:  2017-03-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.